Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The myelin basic protein (MBP)-specific T cell response refers to the immune activity of T lymphocytes that recognize and react to MBP, a major component of the myelin sheath surrounding nerve fibers in the central nervous system. This response is highly relevant in autoimmune diseases such as multiple sclerosis (MS), where autoreactive T cells target MBP, leading to demyelination and neurological dysfunction. Both CD4+ helper and CD8+ cytotoxic T cells can be specific for MBP. Autoreactive T cells recognize specific peptide fragments derived from MBP presented on MHC molecules by antigen-presenting cells. Activation can occur via molecular mimicry: microbial peptides with sequence similarity to MBP may trigger cross-reactive responses that break tolerance and initiate autoimmunity. Central and peripheral tolerance mechanisms exist but are incomplete; self-reactive lymphocytes specific for MBP persist even in healthy individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myelin Basic Protein-Specific T Cell Response (MBP-specific T cell response).